Molecular markers in colorectal cancer: genetic bases for a customised treatment

[1]  P. Lebrun,et al.  3001 ORAL CRYSTAL, a randomized phase III trial of cetuximab plus FOLFIRI vs. FOLFIRI in first-line metastatic colorectal cancer (mCRC) , 2007 .

[2]  S. Groshen,et al.  FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  C. Köhne,et al.  Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial , 2007 .

[4]  P. Catalano,et al.  Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Franck Molina,et al.  Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  E. Korn,et al.  Stage‐specific alterations of the genome, transcriptome, and proteome during colorectal carcinogenesis , 2007, Genes, chromosomes & cancer.

[7]  C. Tournigand,et al.  Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  F. Pruvot,et al.  Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer , 2006, Anti-cancer drugs.

[9]  A. Lièvre,et al.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.

[10]  Yoko Yamamoto,et al.  Prediction of sensitivity of rectal cancer cells in response to preoperative radiotherapy by DNA microarray analysis of gene expression profiles. , 2006, Cancer research.

[11]  W L Allen,et al.  c-FLIP inhibits chemotherapy-induced colorectal cancer cell death , 2006, Oncogene.

[12]  Julian Downward,et al.  Cancer biology: Signatures guide drug choice , 2006, Nature.

[13]  G. Peters,et al.  Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  T. Speed,et al.  Colon cancer prognosis prediction by gene expression profiling , 2005, Oncogene.

[15]  Silvia Benvenuti,et al.  Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. , 2005, The Lancet. Oncology.

[16]  R. Simon,et al.  Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Baiget,et al.  UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer , 2004, British Journal of Cancer.

[18]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[19]  David C. Atkins,et al.  Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  F. Bertucci,et al.  Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters , 2004, Oncogene.

[21]  R. L. Hayward,et al.  Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: Genetic evidence for specificity of the antisense effect. , 2004, Molecular cancer therapeutics.

[22]  Andrew J. Wilson,et al.  Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. , 2003, Cancer research.

[23]  I. Kirsch,et al.  Microsatellite instability in colon cancer. , 2003, The New England journal of medicine.

[24]  M. Ducreux,et al.  Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. , 2003, Cancer research.

[25]  Daniel J Sargent,et al.  Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. , 2003, The New England journal of medicine.

[26]  P. Catalano,et al.  Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Norman Wolmark,et al.  Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  S. Groshen,et al.  Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. , 2002, Journal of the National Cancer Institute.

[29]  H. Blomgren,et al.  Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  S. Groshen,et al.  ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  H. McLeod,et al.  Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. , 2001, International journal of oncology.

[32]  S. Groshen,et al.  A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. , 2001, Anticancer research.

[33]  T. Hunter,et al.  Oncogenic kinase signalling , 2001, Nature.

[34]  J. García-Foncillas,et al.  Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  K. Kinzler,et al.  Role of BAX in the apoptotic response to anticancer agents. , 2000, Science.

[36]  David Joseph,et al.  Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer , 2000, The Lancet.

[37]  S. Groshen,et al.  Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  K. Kinzler,et al.  Disruption of p53 in human cancer cells alters the responses to therapeutic agents. , 1999, The Journal of clinical investigation.

[39]  S. Groshen,et al.  High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  S. Groshen,et al.  p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  D. Kufe,et al.  Identification of Topoisomerase I Mutations Affecting Both DNA Cleavage and Interaction with Camptothecin a , 1996, Annals of the New York Academy of Sciences.

[42]  R. Kerbel,et al.  Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. , 1995, Cancer research.

[43]  B. Vogelstein,et al.  Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response , 1990, Cell.

[44]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[45]  G. Peters,et al.  Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[46]  S. Guichard,et al.  Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. , 2003, European journal of cancer.

[47]  S. Groshen,et al.  Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy , 2001, The Pharmacogenomics Journal.

[48]  B. Vogelstein,et al.  Landscaping the cancer terrain. , 1998, Science.

[49]  R. Diasio,et al.  Severe 5-fluorouracil toxicity in a patient with decreased dihydropyrimidine dehydrogenase activity. , 1993, Cancer investigation.